Literature DB >> 26941095

Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.

Xiao-Lei Shi1, Shanta Mancham2, Bettina E Hansen2, Robert J de Knegt2, Jeroen de Jonge3, Luc J W van der Laan3, Fernando Rivadeneira4, Herold J Metselaar2, Jaap Kwekkeboom5.   

Abstract

BACKGROUND & AIMS: Co-inhibitory receptor-ligand interactions fine-tune immune responses by negatively regulating T cell functions. Our aim is to examine the involvement of co-inhibitory receptor-ligand pair PD-1/PD-L1 in regulating rejection after liver transplantation (LT) in humans.
METHODS: PD-L1/PD-1 expression in liver allograft was determined by immunohistochemistry or flow cytometry, and the effect of blockade was studied using graft-infiltrating T cells ex vivo. Five single nucleotide polymorphisms within PD-1 and PD-L1 genes were genotyped in 528 LT recipients and 410 donors, and associations with both early (⩽6months) and late (>6months) acute rejection were analyzed using Cox proportional-hazards regression model. The effect of PD-L1 rs4143815 on PD-L1 expression was analyzed using donor hepatic leukocytes.
RESULTS: PD-L1 was expressed by hepatocytes, cholangiocytes and along the sinusoids in post-transplant liver allografts, and PD-1 was abundantly expressed on allograft-infiltrating T cells. PD-L1 blockade enhanced allogeneic proliferative responses of graft-infiltrating T cells. In the genetic association analysis, donor PD-L1 rs4143815 (CC/CG vs. GG; HR=0.230; p=0.002) and recipient PD-1 rs11568821 (AA/AG vs. GG; HR=3.739; p=0.004) were associated with acute rejection late after LT in multivariate analysis. Recipients carrying the PD-1 rs11568821 A allele who were transplanted with liver grafts of PD-L1 rs4143815 GG homozygous donors showed the highest risk for late acute rejection. PD-L1 rs4143815 is associated with differential PD-L1 expression on donor hepatic dendritic cells upon IFN-γ stimulation.
CONCLUSION: Our data suggest that interplay between donor PD-L1 and recipient PD-1 counter-regulates rejection activity against liver grafts in humans.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Co-inhibition; Genetic polymorphism; Graft rejection; Liver transplantation; PD-1; PD-L1; T lymphocytes; Tolerance

Mesh:

Substances:

Year:  2016        PMID: 26941095     DOI: 10.1016/j.jhep.2016.02.034

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

Review 1.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

2.  Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance.

Authors:  Yoshihiro Ono; Angelica Perez-Gutierrez; Toshimasa Nakao; Helong Dai; Geoffrey Camirand; Osamu Yoshida; Shinichiro Yokota; Donna Beer Stolz; Mark A Ross; Adrian E Morelli; David A Geller; Angus W Thomson
Journal:  Hepatology       Date:  2018-02-18       Impact factor: 17.425

Review 3.  The CD8 T-cell response during tolerance induction in liver transplantation.

Authors:  Yik Chun Wong; Geoffrey W McCaughan; David G Bowen; Patrick Bertolino
Journal:  Clin Transl Immunology       Date:  2016-10-14

4.  PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.

Authors:  Kostandinos Sideras; Katharina Biermann; Joanne Verheij; Bart R Takkenberg; Shanta Mancham; Bettina E Hansen; Hannah M Schutz; Robert A de Man; Dave Sprengers; Sonja I Buschow; Maddy C M Verseput; Patrick P C Boor; Qiuwei Pan; Thomas M van Gulik; Turkan Terkivatan; Jan N M Ijzermans; Ulrich H W Beuers; Stefan Sleijfer; Marco J Bruno; Jaap Kwekkeboom
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

5.  Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Authors:  Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Yuto Yasuda; Hironori Yoshida; Yoshitaka Yagi; Yuichi Sakamori; Hiroki Nagai; Toyohiro Hirai; Young Hak Kim
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

6.  Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility.

Authors:  Chenyue Qian; Heming Guo; Xiaohong Chen; Aiming Shi; Sicheng Li; Xin Wang; Jie Pan; Chen Fang
Journal:  J Diabetes Res       Date:  2018-11-11       Impact factor: 4.011

Review 7.  Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.

Authors:  Vaia Florou; Sonam Puri; Ignacio Garrido-Laguna; Breelyn A Wilky
Journal:  Ann Transl Med       Date:  2021-06

8.  Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.

Authors:  Zi-Yun Qiao; Zi-Jie Zhang; Zi-Cheng Lv; Huan Tong; Zhi-Feng Xi; Hao-Xiang Wu; Xiao-Song Chen; Lei Xia; Hao Feng; Jian-Jun Zhang; Qiang Xia
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561

Review 9.  Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.

Authors:  Nicolle H R Litjens; Lotte van der Wagen; Jurgen Kuball; Jaap Kwekkeboom
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

10.  Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.

Authors:  Guoying Zhou; Lisanne Noordam; Dave Sprengers; Michail Doukas; Patrick P C Boor; Adriaan A van Beek; Remco Erkens; Shanta Mancham; Dirk Grünhagen; Anand G Menon; Johan F Lange; Pim J W A Burger; Alexandra Brandt; Boris Galjart; Cornelis Verhoef; Jaap Kwekkeboom; Marco J Bruno
Journal:  Oncoimmunology       Date:  2018-04-25       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.